Literature DB >> 2564791

Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse.

A Schattenberg1, T De Witte, M Salden, J Vet, B Van Dijk, D Smeets, J Hoogenhout, C Haanen.   

Abstract

Using red cell phenotyping, cytogenetic analysis of blood lymphocytes, chromosome studies of bone marrow cells, and restriction fragment length polymorphism (RFLP) studies of peripheral blood cells, we demonstrated a high number of mixed chimeras after allogeneic bone marrow transplantation (BMT). Donor marrow from HLA-A, -B, and -DR identical, mixed lymphocyte culture (MLC) nonreactive siblings was depleted of 98% of lymphocytes using counterflow centrifugation. Thirty-two of 48 recipients (67%) appeared to be mixed chimeras at 6 months after transplantation. The high number of mixed chimeras is probably a result of lymphocyte depletion of the marrow graft and the high sensitivity of red cell phenotyping for the demonstration of minor cell populations (at levels as low as 0.01%). The probability of relapse-free survival from 6 months to 4 years after BMT was 85% for the mixed chimeras and 65% for the complete donor chimeras. We conclude that in this study, mixed chimerism is not associated with a higher incidence of relapse.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564791

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Evaluation of mixed chimerism by two-step polymerase chain reaction amplification of hypervariable region MCT118 after allogeneic bone marrow transplantation.

Authors:  J Tanaka; M Kasai; M Imamura; T Higa; S Kobayashi; S Hashino; K Sakurada; T Miyazaki
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

3.  Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats.

Authors:  R A Luhm; D B Bellissimo; A J Uzgiris; W R Drobyski; M J Hessner
Journal:  Mol Diagn       Date:  2000-06

4.  Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation.

Authors:  H Hessel; J Mittermüller; H Zitzelsberger; H U Weier; M Bauchinger
Journal:  Histochem Cell Biol       Date:  1996-11       Impact factor: 4.304

5.  Detection of residual host cells in sex-mismatched bone marrow transplantation in various hematological diseases by fluorescence in situ hybridization.

Authors:  M Arif; K Tanaka; T S Kumaravel; M Eguchi; K Iwato; H Dohy; N Kamada
Journal:  Jpn J Cancer Res       Date:  1997-04

6.  Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.

Authors:  Jörn Erlecke; Isabell Hartmann; Martin Hoffmann; Torsten Kroll; Heike Starke; Anita Heller; Alexander Gloria; Herbert G Sayer; Tilman Johannes; Uwe Claussen; Thomas Liehr; Ivan F Loncarevic
Journal:  Mol Cytogenet       Date:  2009-05-29       Impact factor: 2.009

Review 7.  Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.

Authors:  Livius Penter; Satyen H Gohil; Catherine J Wu
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.